ADMA Biologics, Inc. (ADMA)

ADMA Biologics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	-28.24	-65.9	-71.65	-75.75	-48.28
Depreciation & Amortization	8.33	7.11	5.5	3.94	3.26
Share-Based Compensation	6.19	5.22	3.49	2.86	2.65
Other Operating Activities	22.52	-5.93	-49.71	-33.05	-33.82
Operating Cash Flow	8.8	-59.51	-112.37	-102	-76.19
Capital Expenditures	-4.77	-13.91	-13.51	-12.72	-3.81
Other Investing Activities	-0.21	-	-	-	-
Investing Cash Flow	-4.98	-13.91	-13.51	-12.72	-3.81
Share Issuance / Repurchase	1.1	64.82	121.14	131.21	48.47
Debt Issued / Paid	-25.19	51.71	-0.03	13.52	38.03
Other Financing Activities	-14.91	-7.68	-0.06	-0.83	-6.5
Financing Cash Flow	-38.99	108.85	121.05	143.9	80
Net Cash Flow	-35.17	35.43	-4.83	29.17	-0
Free Cash Flow	4.03	-73.42	-125.88	-114.73	-80.01
Free Cash Flow Margin	1.56%	-47.65%	-155.52%	-271.74%	-272.60%
Free Cash Flow Per Share	0.02	-0.37	-0.90	-1.33	-1.47

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).